SPYRE THERAPEUTICS, INC. (SYRE)
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Acquisition of Own Shares
Wix to Participate in Fireside Chat at Citis 2026 Global Technology Conference
Intuit Reports Fourth Quarter and Full Year Fiscal 2026 Results; Sets Fiscal 2027 Guidance
Lattice to Showcase Industrial FPGA Innovations at FPGAWorld Conference 2026
General Announcement: Minutes of Annual General Meeting held on 29 July 2026
Deep transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder: A meta-analysis of randomized-controlled trials